ALSO NOTED: Novartis gets E.U. nod on Galvus; J&J reps' whistleblower suit tossed out;

> European regulators granted a sigh of relief to Novartis when they OK'd the Swiss drugmaker's type 2 diabetes med Galvus. Report

> Two former reps for Johnson & Johnson saw their whistleblower lawsuit against the company tossed out by a judge this week. Report

> Novartis is proposing to add Ann Fudge, former chairman and CEO of Young & Rubicam Brands, to its board; Fudge also serves on the boards of General Electric and Harvard University. Report

> Mylan got final FDA approval for its generic version of Kytril, Roche's drug for the side effects of cancer treatment. Report

> In an innovative new research pact, scientists from the Medical Research Council in Cambridge and GlaxoSmithKline will collaborate on new work to identify the genetic causes of diseases. Report

> A surge in early-stage drug testing could well set the stage for a spike in lawsuits from patients who feel they've been hurt by the drugs they're volunteering to test, says a new report in The Wall Street Journal. Report

And Finally... Could a drug used to fight a parasite also break into the fortress-like reservoirs HIV builds in the body? Report

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.